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Abstract 
Biomedical and environmental testing currently require access to highly specialized facilities or extensive 
training. Current biochemical tests require complex reagents to achieve a simple human readable result 
such as a color change. This results in low-information tests, with high reagent costs.   To maximize 
information from testing while minimizing costs, biotechnology should leverage complex analysis 
enabled by advanced portable computing power and use simplified reagents. Nanotechnologists have 
created proof-of-concept devices to move diagnosis and monitoring from large core labs to hand-held, 
easy-to-use personal devices, but none have achieved large-scale manufacturability. We demonstrate 
the first economical nanoelectronics produced in a commercial foundry. The mass-manufacture of these 
graphene-based digital biosensors is achieved by successfully integrating delicate graphene material into 
standard electronic high-volume production processes. We describe critical manufacturing parameters 
and the results of biosensing measurements that establish graphene biosensors as a portable, low-cost 
method to gain precise data without labeled, complex reagents. The low power and resource usage of 
these biosensors enable individuals to gain personal, immediate control over precise biological and 
environmental data. 
Introduction 
The world is entering an inflection point in medical and biological testing with the simultaneous 
emergence of improved testing technology, advanced software tools, and increased expectations for 
quality healthcare worldwide. Organizations like the Qualcomm Tricorder XPRIZE and Gates Foundation 
have pushed for integrations of varied technologies in clinical tests to demonstrate potential. Traditional 
healthcare companies such as Abbott market point-of-care tools that perform a limited number of 
assays based on mature assays already cleared by the FDA. In each case, complex, analyte-specific 
reagents and intricate protocols create a need for multiple platforms and deep biochemical expertise to 
replicate the capability of a central lab. This only presents an illusion of portability and democratization 
of biochemical testing. We believe that new label-free measurement tools incorporating graphene 
sensors will remove the need for liquid reagents, decrease power requirements, and shrink the size of 
handheld testing devices. These tools will be capable of performing a wide variety of chemical and 
biochemical assays with a single reader built on a single sensor manufacturing chain, leading to lower 
cost and standardized protocols. 
To demonstrate and validate this approach, we have commercially produced and sold a digital biosensor  
based on graphene-enabled Field Effect Biosensing (FEB). These sensors are a type of Field Effect 
Transistor (FET). They can be described as a type of biologically specialized Ion Sensitive FET (ISFET). We 
describe here the sensing mechanism, demonstrate a label-free capture assay, and summarize the 
critical manufacturing and quality control milestones met during recent sensor production. 
Background theory: 
The unique attributes that are required to build effective field effect biosensors are a combination of 
semiconductor behavior with chemical stability in air and salt water. Only a few materials, such as 
graphene, carbon nanotubes, and molybdenum disulfide have this unique combination of chemical 
stability and electric field sensitivity. This has led to a dense literature covering chemical and biological 
sensors made using these materials1–13. Several attempts were made to produce carbon nanotube 
biosensors for biomedical use in the early part of the 21st century with frustrating results due to 
manufacturing difficulties8. Fabrication techniques using molybdenum disulfide have not matured 
sufficiently for devices to move beyond the proof of concept stage9.  
Previously, we have shown that graphene biosensors can be reliably manufactured in research-oriented 
clean rooms, that the sensors constructed are functional in the hands of independent biologists working 
in both buffer and serum, and that the performance of the sensors is appropriate for diagnostic 
development 4,14,15. In this study, the devices and graphene are manufactured in commercial fabrication 
facilities under industrial quality control processes. This demonstrates, for the first time, movement 
away from theoretically “scalable” nanoelectronics techniques to “scaled” manufacturing. 
 
A diagram of our device architecture is shown in Figure 1a, and a top-down microscopy image of the 
active region of the biosensor is shown in Figure 1b. During measurement, a liquid drop is placed onto 
the circular region defined by the black epoxy shown here. The platinum counter and reference 
electrodes built into the sensor surface control and monitor a voltage in the bulk liquid. A blocking layer 
and embedded biomolecules such as proteins are immobilized onto 15 graphene sensors on the surface. 
The graphene sensor function relies on several overlapping effects, with a basic cartoon of the relevant 
layers shown in Figure 1c. A picture of the complete biosensor is shown in Figure 1d.  
Closest to the graphene channel, the salts in solution will form a well-organized and well-understood 
layer on top of the surface countering any difference in charge between the surface and the liquid. The 
thickness of this layer is the Debye length and is simplified in aqueous solutions to 0.3 √𝑐𝑠⁄  in 
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Figure 1: (a) Diagram of the sensor architecture. Circular sections on top of the graphene represent 
proteins embedded in a blocking layer, represented by curved lines. (b) A microscopy image showing an 
entire sensor surface. Red scalebar is 1 mm. There are fifteen graphene strips grouped into three groups 
of five, exposed through the silicon nitride encapsulation layer. The center of the circuit is the gate 
measurement pad (pseudo-reference) and the large pad surrounding the graphene strips is the liquid 
gate (counter electrode). (c) Diagram of the sensor regions near the graphene. The double layer region 
is 0.3/√𝑐𝑠 nm tall, where 𝑐𝑠 is the ionic strength of the bulk solution. The Donnan equilibrium region is 
the thickness of the combined protein and blocking layer on the surface. (d) Picture of the complete 
biosensor.  
nanometers, with 𝑐𝑠 the ionic strength of the solution. The Donnan effect region extends beyond the 
Debye length, extending through the thickness of an ion-permeable membrane immobilized to the 
surface.  The voltage in the bulk liquid is controlled by conventional electrochemical means.  From an 
electrical perspective, the system can be understood with the bulk liquid as the gate of a transistor, and 
the combined Donnan region and Debye length as the dielectric between the graphene channel and the 
gate. From a biological perspective, the system can be understood as a voltage sensitive membrane 
incorporating proteins with driven voltages, like action potentials, in the bulk liquid. The model below 
explains how sensing is accomplished for binding interactions, even when charge transfer is not 
involved. 
𝐼 ≈  
 𝑊 
𝐿 
 𝜇 𝐶𝑔 𝑉𝑠𝑑(𝑉0 − 𝑉𝑔 + 2.3 𝜙𝑡ℎ𝛼 Δ𝑝𝐻 + (1 − 𝛼)Δ𝜑𝐷) (1) 
Equation 1 shows a modification of previously developed compact models for graphene FETs when 
combined with ISFET models16–21. This model generally relates the current (𝐼) to typical electrical 
properties such as the charge carrier mobility (𝜇), capacitance per unit area to the gate (𝐶𝑔), width (𝑊) 
and length (𝐿) of the graphene channel, source-drain voltage applied directly to the graphene (𝑉𝑠𝑑) and 
the gate voltage (𝑉𝑔) relative to the Dirac voltage (𝑉0). The Dirac voltage here is the gate voltage at 
which there is a minimum in conduction at neutral pH. The capacitance between the graphene and the 
liquid, 𝐶𝑔, is a series combination of the graphene quantum capacitance, the double layer capacitance, 
and a capacitance across the immobilized layer due to the Donnan effect22,23. 
The remaining terms are corrections to the gate voltage due to the influence of pH changes and the 
Donnan potential. This model assumes operation of the sensor near room temperature, for an 
equivalent gate voltage less than the Dirac voltage, for source-drain voltages below 1 V, and for a 
channel length greater than 10 μm. 
Electronic sensitivity to pH is typically attributed to hydrogen binding to a gate dielectric. For graphene 
transistors, there is no gate dielectric, but this form of pH sensitivity has been shown to apply through 
direct shifts in the apparent Dirac voltage17,24. The surface pH sensitivity factor (𝛼), is a material 
dependent value. For clean isolated graphene, 𝛼 is a very low 0.02, but in practice this value is increased 
by the presence of oxides and nitrides used in device fabrication; 𝛼 values for practical graphene 
transistors are around 0.3725–27.  This term is combined with the thermal voltage (𝜙𝑡ℎ), about 26 mV, 
and pH shift from a neutral surface (Δ𝑝𝐻) to produce the equivalent gate voltage due to pH. 
A Donnan potential (Δ𝜑𝐷) is created when an ion-permeable layer separates 2 collections of ions, as 
shown in equation 2.  
Δ𝜑𝐷 = 𝜙𝑡ℎ 𝑙𝑛
(√4𝑐𝑠2+𝑐𝑥2+𝑐𝑥)
2 𝑐𝑠
(2)
In this case, the immobilized layer of proteins, peptides, surfactants, PEG, or other soft molecules 
separate the graphene channel and double-layer from the bulk solution. Any charges or dipoles leading 
to a net charge within that immobilized ion permeable layer (𝑐𝑥) will require an extra accumulation of a 
counter-ion within the layer to maintain charge neutrality. This difference in the concentration of ions 
between the bulk solution (𝑐𝑠) and that in the immobilized protein layer creates a Donnan potential
20,28. 
This additional potential enables sensing beyond the Debye screening length,19,22,29 and has been 
demonstrated repeatedly with graphene biosensors4,7,12,14,30. 
Results 
Chemical Measurements 
This model provides a relatively simple framework for thinking about how a graphene-based digital 
biosensor works. Practical function of the biosensor is demonstrated by performing sensing 
measurements. We start by evaluating the basic response of the biosensors to common background 
effects such as shifts in pH and ionic strength.  
Our sensor data is analyzed by calculating the percent change in current from a baseline taken in assay 
buffer. This removes the effect of variations in resistance sensor-to-sensor. Additionally, the change in 
current relative to a controlled change in gate voltage Δ𝐼/Δ𝑉𝑔 is used to isolate responses due to change 
in gate capacitance 𝐶𝑔, independent of direct potential shifts from pH and Donnan potential. To 
generate the data in the Figure 2, the standard Agile R100 measurement settings were used, which limit 
applied voltages to between +/- 100 mV4,14. The chip fabrication process purposefully creates a shift of 
the Dirac voltage to greater than 100 mV, so that Δ𝐼/Δ𝑉𝑔 is approximately linear over all applied 𝑉𝑔. This 
simplifies and speeds up practical biosensor measurement and analysis, while unfortunately preventing 
direct measurements of the Dirac voltage.    
 
Figure 2: (a) Change in current due to change in pH. Fit is linear 
with a slope of -3.2% per pH unit. (b) Change in current due to 
change in ionic strength, when pH is held constant. Fit is linear 
with a slope of 3.0% per molar unit of NaCl. (c) Change in slope 
(dI/dVg) due to change in pH. Fit is linear with a slope of 5.9% 
per pH unit. (d) Change in slope due to change in ionic strength.  
Response is fit to -0.3 √[𝑁𝑎𝐶𝑙] 
(a) (b) 
(c) (d) 
The solutions used in Figure 2a and 2c are standard 1X phosphate buffered saline (PBS) pH 7.4 with 
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Figure 3: (a) Diagram of the steps 
of protein immobilization and 
measurement used here. First, 
antibodies against IL-6 are 
immobilized, then PEG is added as 
a block, then measurements are 
performed with IL-6. (b) Change in 
current and (c) change in slope for 
23 different sensors during 
immobilization process. Shading is 
used to delineate steps: 
calibration in MES buffer, COOH 
activation by EDC/NHS incubation 
in MES buffer, wash in MES, 
antibody incubation in PBS, PEG 
incubation in PBS, quench in 
ethanolamine, wash in PBS.  
varying amounts of 100 mM HCl added to adjust the pH. The pH value was set first at pH 7, and then 
measurements were performed at increasing pH values. The solutions used in Figure 2b and 2d are NaCl 
in deionized water. 
The most notable feature of the data in Figure 2 is the dependence of the gate response slope on the 
square root of the ion concentration. In Equation 1, both 𝛼 and 𝐶𝑔 are dependent on the ion 
concentration, but the double layer capacitance component of 𝐶𝑔 is simplified to 𝜀 √𝑐𝑠 0.3⁄ . The 
observed and modeled dependency of these sensors on pH and ionic strength indicates an ability to 
generate broad and complex responses, capable of creating signatures for diverse biological 
macromolecules and their complexes.  
Protein Measurements 
To demonstrate measurement of a biological interaction, a monoclonal antibody against human 
interleukin-6 (anti-IL6) and recombinant human IL-6 (IL6) were used from a commercial ELISA kit.  Anti-
IL6 was immobilized on graphene chips with a prepared carboxyl surface and activated via EDC/sNHS 
(Figure 3), as described previously4. Timing for each of the liquid exchange steps is described in the 
methods section. All liquid exchanges are done via an aspirator and manual pipette. Aspiration of liquid 
from the sensor surface briefly removes the liquid gate, prior to re-establishing the gate with pipetting 
of new liquid to the surface. This leads to the spikes in the data at the white/grey junctions.  
Figure 3b and 3c show the percent change in current and slope responses for 23 different sensors all 
following the same immobilization protocol with the same anti-IL6 reagent. The immobilization data 
shows consistent trends. Addition of EDC and sNHS after calibration always leads to a decrease in 
current, without a change in slope. Addition of the antibody at 30 minutes leads to a further decrease in 
current and a large increase in slope. This change is likely due to switching from the pH 6.0 MES buffer 
used during carboxyl activation to the pH 7.4 PBS pH buffer used during antibody incubation.  Addition 
of PEG-amine after anti-IL6 immobilization always leads to a small decrease in current and a small 
increase in slope. This is consistent with association of PEG to the surface to serve as a blocking layer 
around immobilized protein. Addition of ethanolamine (pH 8.0) quenches any remaining activated 
carboxyl groups, and always causes a large decrease in current and a large increase in slope. Rinsing with 
PBS (pH 7.4) then raises the current and decreases the slope, although never back to the initial starting 
position. This repeatable set of chemistry and sensor responses indicates both reproducibility of 
response sensor-to-sensor as well as demonstrable, permanent change to the surface chemistry of the 
chips due to the immobilization process. The sign of the responses we see during immobilization are 
consistent with the expected responses from the pH changes measured on bare graphene chips shown 
in Figure 2. However, the magnitude of responses is significantly higher. As pyrene, antibody, and PEG 
are added to the chip, a layer supporting a Donnan effect voltage is created.  
 The effectiveness of this immobilization process is demonstrated in the sensing measurements shown in 
Figure 4. Different concentrations of IL-6 in PBS were applied to the anti-IL6 immobilized chips. The 
different concentrations of IL6 lead to different response magnitudes and different speeds of 
interaction, as expected by any kinetic binding measurement. This data compares well with the metrics 
provided by the ELISA kit from which the reagents were taken. When running an ELISA with this kit, the 
expected sensitivity is <2 pg/mL (FEB sensitivity is <2 pg/mL), and the standard range of response is 
between 7.8 pg/mL and 500 pg/mL (FEB range of response is 2 pg/mL to 1000 pg/mL). Here, we have 
reproduced the ELISA quality while adding kinetics. We have removed the need for labels while 
providing more information-dense real-time data than an end-point assay technique like ELISA. 
Scaled Manufacturing 
The data shown here establishes that the devices we have manufactured are similar in function to other 
biosensors in the graphene literature. A major hurdle to providing graphene biosensors to biological 
researchers is the typical manufacture of nanoelectronics in research-oriented clean rooms by teams of 
research scientists. Previously, there was no nanoelectronic manufacturing approaching ISO9001 
standards or Good Manufacturing Practices (GMP), despite those requirements for commercial and 
clinical applications.   
The facilities used to manufacture chips are located at Rogue Valley Microelectronics, Nanomedical 
Diagnostics (“Nanomed”), and Samtec. Rogue Valley used a 150 mm MEMS processing line, without 
modification to staff or equipment to process graphene wafers. The Samtec facility similarly used 
established silicon chip packaging equipment, staff, and traceable processes to package these graphene 
chips. 
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Figure 4: (a) Change in gate slope of sensors functionalized with 
antibodies against IL-6 to different concentrations of IL6. (b) Change in 
current for the same sensors. 
Graphene is grown and transferred at Nanomed using automation of a previously described process4. 
The marginal cost for graphene, when using an automated system such as ours, is $0.019 per cm2. This 
comes from our average cost of copper foil of $0.012 per cm2 and the cost of power to run the furnaces, 
which in California is currently $0.007 per cm2 of grown graphene. This is less than the price of silicon 
wafer substrates for this work, $0.40 per cm2 for 150 mm wafers. The cost of processing wafers is 20x 
greater than the cost of the graphene raw material, making the processing the dominant cost factor in 
producing a commercial graphene device and not the graphene raw material cost. 
Our process for manufacturing digital biosensors starts with deposition and patterning of a metallization 
layer that creates the routing for the source-drain voltage on 15 graphene transistors per die, as well as 
the platinum reference and counter electrodes. Graphene is grown and transferred onto the wafer. 
After deposition, graphene is etched using a hard mask and an oxygen plasma. A silicon nitride 
encapsulation layer is deposited via PECVD. Windows are etched into the silicon nitride down to the 
graphene hard mask. Wafers are diced and packaged via a chip-on-board process, where an epoxy is 
used to protect wirebonds and define the liquid wetted area. After packaging, the chips are annealed 
and undergo strict QA processes to ensure reproducible quality. 
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Figure 5: (a) Histogram of test resistances from 5543 chips. Fit is a log-normal 
distribution with a peak at 13.6 kOhm and a standard deviation of 9.2 kOhm.  (b) 
Microscopy image of defect-free graphene sensor (c) Microscopy image of a graphene 
sensor with minor polymer contamination highlighted by the red arrow. (d) 
Microscopy image of a graphene sensor with major graphene tearing highlighted by 
the red arrow. (e) Wafer yield map combining data from 27 wafers, showing 
cumulative % yield for each die. 
Figure 5 presents quality assurance data from three production lots comprising twenty seven 150 mm 
wafers and 7,992 chips produced over the course of one year. Quality control processes focus on 
reproducibility and cost rather than searching for occasional outstanding performance. Specifically, this 
means that we use automated optical microscopy to search for contamination and graphene tearing 
over entire wafers, rather than using nanotechnology specialized hardware such as atomic force 
microscopy or Raman spectroscopy. Differential interference contrast microscopy is used along with AI-
enabled defect identification to perform optical evaluations, such as those shown in Figure 5. Table 1 
shows the distribution of defects found via optical microscopy across all 27 wafers. Minor defects 
generally do not prevent a chip from passing to the next stage of manufacture, while major defects 
always prevent a chip from continuing.  A chip may have no defects, a single defect, or multiple defects. 
Table 1 Defect frequency. 
Issue number  Percent of Errors 
Minor Polymer Contamination 4,066 44.2% 
Minor Tears 2,857 31.0% 
Major Tears 1,742 18.9% 
Major Polymer Contamination    295 3.2% 
Major Lithography Defect      147 1.6% 
Minor Lithography Defect      77 0.8% 
Other      22 0.2% 
After optical QA, electrical QA is performed. Figure 5a shows a histogram of resistances from 5,543 
chips. This data can be fit with a log normal distribution, with a peak of 13.6 kΩ ± 9.2 kΩ. The length of 
the measured graphene strips is 300 m, with a width of 10 m. Five strips are measured in parallel, for 
a typical resistance/sq of 2.3 kΩ/sq. Transistors that have resistances outside a range from 1 kΩ to 100 
kΩ fail electrical QA. This bounds the power draw per sensor channel at between 1 nW to 100 nW when 
using our standard 10 mV 𝑉𝑠𝑑. This low power draw anticipates the need for thousands of chemically 
differentiated sensor channels or other graphene transistors in a portable form factor. 
At the end of the QA process, a map of yielded dies on the wafer is produced. Combining maps from 
27 wafers shows a clear bias for failure at the edge of the wafers, probably indicating damage to the 
graphene transistors or lithography due to handling or normal edge effects. For example, major 
lithography defects occur predominantly at the wafer edge. Together the data in Figure 5e shows a 
percent yield by die position, with an overall average of 52%, a value that compares well with silicon 
device yields in the early 1980s31. 
Discussion 
For the past year, we have produced and sold graphene sensors for biological researchers following 
these described processes. We present the first complete characterization of this fusion of electronics 
and biochemistry. This marks a break from the past few decades of great feats of artisanal 
nanoelectronics and demonstrates the potential for graphene biosensors to serve as the interface 
between biochemistry and digital analysis.  
A core challenge has been making the transition from an expensive, variable sensor to a cost-efficient, 
consistent batch-to-batch manufactured sensor. A key to that transition is following a rigorous 
specification and quality control process appropriate for a biologist end user rather than a 
nanotechnologist. While the manufacturing and QA processes described here were used to create 
graphene-based biosensors, these processes are broadly enabling for many electronics applications 
using graphene and other nanomaterials. 
The demonstrated biological sensing capability, low power requirements, and compact size of graphene-
based biosensors will enable development of the next generation of biochemical applications. With the 
most difficult piece of the puzzle – cost-effective large-scale manufacturing – solved, low-power, 
portable digital biosensors can significantly impact healthcare industries with innovative new products 
that enable cutting-edge life science research, drug discovery applications, and diagnostic and health 
monitoring platforms.  
Methods 
The Agile R100 system was used for all measurements. The standard electrical settings were used. The 
gate voltage was swept between ± 100 mV in a triangle wave at a slow speed of 0.3 Hz, while 𝑉𝑠𝑑 was 
held at 10 mV. These voltage ranges were selected to minimize the electric fields on the proteins. Agile 
Plus software was used to run the hardware. 
Except where noted, 1X phosphate buffered saline solution pH 7.4 (PBS) (ThermoFisher # 10010031) 
was used for calibration and measurement. HCl was used to create PBS solutions of varying pH from 5.8 
to 7.5, measured with a calibrated glass electrode pH meter. Fifty millimolar 2-(N-
morpholino)ethanesulfonic acid buffer pH 6.0 (MES) (Alfa Aesar # J62574-AK, diluted in DI water) was 
used for crosslinking chemistry. EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) 
(Amresco # N195) was used with sNHS (N-hydroxysulfosuccinimide) (G Biosciences # BC97) to activate 
carboxyl groups for amine attachment. For ionic strength measurements, deionized water was used for 
calibration, and concentrations of NaCl from 0.25 M to 2 M in deionized water were used for the 
measurement. Agile FLEX biosensor chips (Nanomed) were used for pH and ionic strength 
measurements. 
Anti-IL6 and IL6 were purchased as part of an ELISA kit (ThermoFisher # KHC0062). 
Agile COOH biosensor chips (Nanomed) were used for IL6 measurements. COOH chips are prepared via 
incubation of clean graphene chips with 3mM pyrene-carboxylic acid (TCI # P1687) in methanol for two 
hours. 
The detailed process for anti-IL6 immobilization is: After calibration in 50 mM MES pH 6.0 for 5 minutes, 
2.08 mM EDC and 5.53 mM sNHS in 50 mM MES pH 6.0 was incubated for 20 minutes. The chips were 
rinsed 2 times with 50 mM MES pH 6.0, followed by 14.6 nM anti-IL-6 in 1X PBS pH 7.4 for 15 minutes. 
Then, 3 mM PEG-amine (Broadpharm Item #BP-22355) in PBS was incubated for 15 minutes to block the 
surface, followed by 1 M ethanolamine pH 8.0 (Alfa Aesar Cat# L14322) for 15 minutes to deactivate any 
remaining carboxyl groups. Finally, the biosensor chips were rinsed 5 times in PBS, and the last rinse was 
incubated for 5 minutes to stabilize the signal prior to measurement. This process was performed with a 
hand pipette following software prompts. 
Prime Si, 150mm, P-type wafers were purchased from Rogue Valley Microdevices, as was all mask 
fabrication and lithography. A wet thermal oxide of 3,000 Å was first grown. A metallization layer of 100 
Å Cr and 500 Å Pt was patterned via liftoff.  
Graphene was grown via chemical vapor deposition at Nanomed on copper and transferred to the wafer 
via bubble transfer. Microscopy was used to evaluate graphene quality at every transistor location prior 
to further processing.  
At Rogue Valley Microdevices, a 1,000 Å Au layer was deposited on the graphene and etched to form a 
hard mask. An oxygen plasma etch was used to remove excess graphene. A 5,000 Å SiN layer was 
deposited via PECVD, patterned and etched via RIE.    
Custom PCBs for packaging were designed by Varasco Engineering, laid out by Pacific Design, and 
purchased from Consisys. Samtec diced wafers after microfabrication and performed a standard chip-
on-board packaging process using gold wirebonds and a custom dam-and-fill encapsulation pattern to 
create the liquid well on the sensor.  
The chips are cleaned, vacuum annealed at 200 C, and inspected at Nanomed.  
Optical microscopy is performed using an nSPEC microscope (Nanotronics). AI driven automated defect 
identification software is also provided by Nanotronics. 
Electrical QA is performed using an Agile R100 (Nanomed) in QA mode. 
The datasets generated during and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
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